Indeed Snapshot

Track Champions Oncology reviews on Indeed to uncover insights on employee sentiment

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Profile Url Name Website Industry Description Revenue Headquarters location CEO Rating: CEO (%) Rating: CEO Responses Count Rating: Overall Happiness: Compensation score Happiness: Support score Happiness: Purpose score Happiness: Flexibility score Happiness: Energy score Happiness: Work Happiness score Happiness: Trust score Happiness: Learning score Happiness: Belonging score Happiness: Inclusion score Happiness: Overall score Happiness: Appreciation score Happiness: Achievement score Happiness: Responses Count Review Count Ratings Responses Count Rating: Culture & Values Rating: Compensation & Benefits Rating: Job Security & Advancement Rating: Senior Management Rating: Worklife Balance Interview: Duration Responses count Interview Duration Interview: Difficulty Responses count Interview Difficulty Interview: Experience Responses count Interview Experience Work Culture: Stressful (0) to Relaxed (1) Ratio Work Culture: Slow Paced (0) to Fast Paced (1) Ratio Work Culture: Competitive (0) to Collaborative (1) Ratio Date Added Date Updated Company Name Sector Industry
nasdaq:csbr https://www.indeed.com/cmp/champions-oncology,-inc. Aug 29th, 2022 12:00AM Open Champions Oncology, Inc. Pharmaceutical & Biotechnology Champions Oncology is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Champions TumorGraft® (CTG) platform is a novel approach based upon the implantation of primary human tumors in immune-deficient mice followed by propagation of the resulting engraftments, or patient-derived xenografts (PDX) models, in a manner that preserves the biological characteristics of the original human tumor. Champions believes that these PDX models closely reflect human cancer biology and that their response to drugs is more predictive of clinical outcomes in cancer patients. Champions is building its CTG platform through the procurement, development and characterization of TumorGrafts within multiple cancer types. Champions TumorGraft® PDX models are procured through agreements with a number of institutions in the U.S. and overseas, as well as through the company’s Personalized Oncology Solutions business. RRv1_25M_100M Laboratory: 1330 Piccard Drive Suite 025 Rockville, MD 20850 2.60 13.00 13.00 2.20 2.40 2.50 2.30 2.00 12.00 About two weeks 12.00 EASY 11.00 FAVORABLE Aug 29th, 2022 11:49AM Aug 29th, 2022 11:49AM Champions Oncology
nasdaq:csbr https://www.indeed.com/cmp/champions-oncology,-inc. Aug 28th, 2022 12:00AM Open Champions Oncology, Inc. Pharmaceutical & Biotechnology Champions Oncology is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Champions TumorGraft® (CTG) platform is a novel approach based upon the implantation of primary human tumors in immune-deficient mice followed by propagation of the resulting engraftments, or patient-derived xenografts (PDX) models, in a manner that preserves the biological characteristics of the original human tumor. Champions believes that these PDX models closely reflect human cancer biology and that their response to drugs is more predictive of clinical outcomes in cancer patients. Champions is building its CTG platform through the procurement, development and characterization of TumorGrafts within multiple cancer types. Champions TumorGraft® PDX models are procured through agreements with a number of institutions in the U.S. and overseas, as well as through the company’s Personalized Oncology Solutions business. RRv1_25M_100M Laboratory: 1330 Piccard Drive Suite 025 Rockville, MD 20850 2.60 13.00 13.00 2.20 2.40 2.50 2.30 2.00 12.00 About two weeks 12.00 EASY 11.00 FAVORABLE Aug 28th, 2022 04:48AM Aug 28th, 2022 04:48AM Champions Oncology
nasdaq:csbr https://www.indeed.com/cmp/champions-oncology,-inc. Aug 27th, 2022 12:00AM Open Champions Oncology, Inc. Pharmaceutical & Biotechnology Champions Oncology is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Champions TumorGraft® (CTG) platform is a novel approach based upon the implantation of primary human tumors in immune-deficient mice followed by propagation of the resulting engraftments, or patient-derived xenografts (PDX) models, in a manner that preserves the biological characteristics of the original human tumor. Champions believes that these PDX models closely reflect human cancer biology and that their response to drugs is more predictive of clinical outcomes in cancer patients. Champions is building its CTG platform through the procurement, development and characterization of TumorGrafts within multiple cancer types. Champions TumorGraft® PDX models are procured through agreements with a number of institutions in the U.S. and overseas, as well as through the company’s Personalized Oncology Solutions business. RRv1_25M_100M Laboratory: 1330 Piccard Drive Suite 025 Rockville, MD 20850 2.60 13.00 13.00 2.20 2.40 2.50 2.30 2.00 12.00 About two weeks 12.00 EASY 11.00 FAVORABLE Aug 27th, 2022 04:07AM Aug 27th, 2022 04:07AM Champions Oncology
nasdaq:csbr https://www.indeed.com/cmp/champions-oncology,-inc. Aug 25th, 2022 12:00AM Open Champions Oncology, Inc. Pharmaceutical & Biotechnology Champions Oncology is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Champions TumorGraft® (CTG) platform is a novel approach based upon the implantation of primary human tumors in immune-deficient mice followed by propagation of the resulting engraftments, or patient-derived xenografts (PDX) models, in a manner that preserves the biological characteristics of the original human tumor. Champions believes that these PDX models closely reflect human cancer biology and that their response to drugs is more predictive of clinical outcomes in cancer patients. Champions is building its CTG platform through the procurement, development and characterization of TumorGrafts within multiple cancer types. Champions TumorGraft® PDX models are procured through agreements with a number of institutions in the U.S. and overseas, as well as through the company’s Personalized Oncology Solutions business. RRv1_25M_100M Laboratory: 1330 Piccard Drive Suite 025 Rockville, MD 20850 2.60 13.00 13.00 2.20 2.40 2.50 2.30 2.00 11.00 About a week 11.00 EASY 11.00 FAVORABLE Aug 25th, 2022 08:47AM Aug 25th, 2022 08:47AM Champions Oncology
nasdaq:csbr https://www.indeed.com/cmp/champions-oncology,-inc. Aug 23rd, 2022 12:00AM Open Champions Oncology, Inc. Pharmaceutical & Biotechnology Champions Oncology is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Champions TumorGraft® (CTG) platform is a novel approach based upon the implantation of primary human tumors in immune-deficient mice followed by propagation of the resulting engraftments, or patient-derived xenografts (PDX) models, in a manner that preserves the biological characteristics of the original human tumor. Champions believes that these PDX models closely reflect human cancer biology and that their response to drugs is more predictive of clinical outcomes in cancer patients. Champions is building its CTG platform through the procurement, development and characterization of TumorGrafts within multiple cancer types. Champions TumorGraft® PDX models are procured through agreements with a number of institutions in the U.S. and overseas, as well as through the company’s Personalized Oncology Solutions business. RRv1_25M_100M Laboratory: 1330 Piccard Drive Suite 025 Rockville, MD 20850 2.60 13.00 13.00 2.20 2.40 2.50 2.30 2.00 11.00 About a week 11.00 EASY 11.00 FAVORABLE Aug 23rd, 2022 10:40AM Aug 23rd, 2022 10:40AM Champions Oncology
nasdaq:csbr https://www.indeed.com/cmp/champions-oncology,-inc. Aug 21st, 2022 12:00AM Open Champions Oncology, Inc. Pharmaceutical & Biotechnology Champions Oncology is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Champions TumorGraft® (CTG) platform is a novel approach based upon the implantation of primary human tumors in immune-deficient mice followed by propagation of the resulting engraftments, or patient-derived xenografts (PDX) models, in a manner that preserves the biological characteristics of the original human tumor. Champions believes that these PDX models closely reflect human cancer biology and that their response to drugs is more predictive of clinical outcomes in cancer patients. Champions is building its CTG platform through the procurement, development and characterization of TumorGrafts within multiple cancer types. Champions TumorGraft® PDX models are procured through agreements with a number of institutions in the U.S. and overseas, as well as through the company’s Personalized Oncology Solutions business. RRv1_25M_100M Laboratory: 1330 Piccard Drive Suite 025 Rockville, MD 20850 2.60 13.00 13.00 2.20 2.40 2.50 2.30 2.00 11.00 About a week 11.00 EASY 11.00 FAVORABLE Aug 21st, 2022 12:24PM Aug 21st, 2022 12:24PM Champions Oncology
nasdaq:csbr https://www.indeed.com/cmp/champions-oncology,-inc. Aug 20th, 2022 12:00AM Open Champions Oncology, Inc. Pharmaceuticals Champions Oncology is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Champions TumorGraft® (CTG) platform is a novel approach based upon the implantation of primary human tumors in immune-deficient mice followed by propagation of the resulting engraftments, or patient-derived xenografts (PDX) models, in a manner that preserves the biological characteristics of the original human tumor. Champions believes that these PDX models closely reflect human cancer biology and that their response to drugs is more predictive of clinical outcomes in cancer patients. Champions is building its CTG platform through the procurement, development and characterization of TumorGrafts within multiple cancer types. Champions TumorGraft® PDX models are procured through agreements with a number of institutions in the U.S. and overseas, as well as through the company’s Personalized Oncology Solutions business. RRv1_25M_100M Laboratory: 1330 Piccard Drive Suite 025 Rockville, MD 20850 2.60 13.00 13.00 2.20 2.40 2.50 2.30 2.00 11.00 About a week 11.00 EASY 11.00 FAVORABLE Aug 20th, 2022 02:00PM Aug 20th, 2022 02:00PM Champions Oncology
nasdaq:csbr https://www.indeed.com/cmp/champions-oncology,-inc. Aug 19th, 2022 12:00AM Open Champions Oncology, Inc. Pharmaceutical & Biotechnology Champions Oncology is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Champions TumorGraft® (CTG) platform is a novel approach based upon the implantation of primary human tumors in immune-deficient mice followed by propagation of the resulting engraftments, or patient-derived xenografts (PDX) models, in a manner that preserves the biological characteristics of the original human tumor. Champions believes that these PDX models closely reflect human cancer biology and that their response to drugs is more predictive of clinical outcomes in cancer patients. Champions is building its CTG platform through the procurement, development and characterization of TumorGrafts within multiple cancer types. Champions TumorGraft® PDX models are procured through agreements with a number of institutions in the U.S. and overseas, as well as through the company’s Personalized Oncology Solutions business. RRv1_25M_100M Laboratory: 1330 Piccard Drive Suite 025 Rockville, MD 20850 2.60 13.00 13.00 2.20 2.40 2.50 2.30 2.00 11.00 About a week 11.00 EASY 11.00 FAVORABLE Aug 19th, 2022 12:24PM Aug 19th, 2022 12:24PM Champions Oncology
nasdaq:csbr https://www.indeed.com/cmp/champions-oncology,-inc. Aug 18th, 2022 12:00AM Open Champions Oncology, Inc. Pharmaceutical & Biotechnology Champions Oncology is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Champions TumorGraft® (CTG) platform is a novel approach based upon the implantation of primary human tumors in immune-deficient mice followed by propagation of the resulting engraftments, or patient-derived xenografts (PDX) models, in a manner that preserves the biological characteristics of the original human tumor. Champions believes that these PDX models closely reflect human cancer biology and that their response to drugs is more predictive of clinical outcomes in cancer patients. Champions is building its CTG platform through the procurement, development and characterization of TumorGrafts within multiple cancer types. Champions TumorGraft® PDX models are procured through agreements with a number of institutions in the U.S. and overseas, as well as through the company’s Personalized Oncology Solutions business. RRv1_25M_100M Laboratory: 1330 Piccard Drive Suite 025 Rockville, MD 20850 2.60 13.00 13.00 2.20 2.40 2.50 2.30 2.00 11.00 About a week 11.00 EASY 11.00 FAVORABLE Aug 18th, 2022 04:08AM Aug 18th, 2022 04:08AM Champions Oncology
nasdaq:csbr https://www.indeed.com/cmp/champions-oncology,-inc. Aug 17th, 2022 12:00AM Open Champions Oncology, Inc. Pharmaceutical & Biotechnology Champions Oncology is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Champions TumorGraft® (CTG) platform is a novel approach based upon the implantation of primary human tumors in immune-deficient mice followed by propagation of the resulting engraftments, or patient-derived xenografts (PDX) models, in a manner that preserves the biological characteristics of the original human tumor. Champions believes that these PDX models closely reflect human cancer biology and that their response to drugs is more predictive of clinical outcomes in cancer patients. Champions is building its CTG platform through the procurement, development and characterization of TumorGrafts within multiple cancer types. Champions TumorGraft® PDX models are procured through agreements with a number of institutions in the U.S. and overseas, as well as through the company’s Personalized Oncology Solutions business. RRv1_25M_100M Laboratory: 1330 Piccard Drive Suite 025 Rockville, MD 20850 2.60 13.00 13.00 2.20 2.40 2.50 2.30 2.00 11.00 About a week 11.00 EASY 11.00 FAVORABLE Aug 17th, 2022 09:46AM Aug 17th, 2022 09:46AM Champions Oncology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.